Clinical Trial Update: Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated tislelizumab (BGB-A317) as neoadjuvant therapy for colorectal cancer and reported efficacy and safety results. The study is completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-02-13